Literature DB >> 3359567

Isotypic distribution of anti-double-stranded DNA antibodies: a diagnostic evaluation by enzyme-linked immunosorbent assay.

J L Preud'homme1, E Rochard, D Gouet, F Danon, M Alcalay, G Touchard, P Aucouturier.   

Abstract

Anti-native DNA antibodies were studied using an immunoglobulin class-specific enzyme-linked immunosorbent assay (ELISA) in 450 sera, virtually all of which were antinuclear antibody positive. ELISA was positive in about 85% of systemic lupus erythematosus (SLE) sera, usually at high titer and for two or three isotypes. Virtually all sera with antibodies of the three main classes were collected from SLE patients. Very high titers were unique to SLE. In contrast, low-titer antibodies of a single, mostly IgM, class were found in certain patients without evidence of autoimmune disease or with non-SLE autoimmune diseases. The isotypy and titer of the antibodies hence appear to be critical parameters for a correct interpretation of results. Under these conditions, ELISA seems to be usable as single screening test for the demonstration of anti-DNA antibodies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3359567

Source DB:  PubMed          Journal:  Diagn Clin Immunol        ISSN: 0895-0458


  3 in total

Review 1.  The use of laboratory tests in the diagnosis of SLE.

Authors:  W Egner
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

2.  Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis.

Authors:  Amélie Servettaz; Niloufar Kavian; Carole Nicco; Vanessa Deveaux; Christiane Chéreau; Andrew Wang; Andreas Zimmer; Sophie Lotersztajn; Bernard Weill; Frédéric Batteux
Journal:  Am J Pathol       Date:  2010-05-27       Impact factor: 4.307

3.  Characterization of a human monoclonal autoantibody directed to cardiolipin/beta 2 glycoprotein I produced by chronic lymphocytic leukaemia B cells.

Authors:  X Mariette; Y Levy; M L Dubreuil; L Intrator; F Danon; J C Brouet
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.